Using registry records to study nonacog beta pegol safety
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at safety information using existing patient registry records, not new treatment visits. It may help researchers better understand side effects of nonacog beta pegol by using real-world data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are listed in the PedNet registry and/or the EUHASS safety system
- You may qualify if you are in another national or international hemophilia safety registry
- No special clinic visit or treatment is required for eligibility, since the study uses existing records
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows males with Hemophilia B who are already on preventive (prophylaxis) treatment with Rebinyn/Refixia (a factor replacement medicine). It mainly looks at safety and how treatment is used over time, especially in people starting or continuing this prophylaxis plan.
This study collects and reviews side-effect information from the EUHASS registry in people with hemophilia. It may help doctors better understand how turoctocog alfa pegol (a clotting medicine) is tolerated in real-world care.
This trial is a patient registry that collects medical information from children with hemophilia A or B. It may help care teams better understand bleeding patterns and treatments over time across participating hospitals.
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
This study looks at how well a medicine called damoctocog alfa pegol (Jivi) works to prevent bleeding in children with hemophilia A. It will follow children who are already using this medicine or starting it, to see how effective it is in real life.
This registry collects information from people with hemophilia who have had gene therapy, to track safety and how well it works over time. By joining, you help improve future treatments for others.
Hear when a new Haemophilia B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.